Press Release: BioSyent Releases Financial Results for Q3 and YTD 2026

Dow Jones06:45

MISSISSAUGA, Ontario, Nov. 17, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. ("BioSyent", TSX Venture: RX) released today its consolidated financial results for the three months (Q3), nine months (YTD), and trailing twelve months (TTM) ended September 30, 2026. Key highlights include:

 
                              % Change                % Change                  % Change 
                               vs. Q3                 vs. YTD     TTM Sep    vs. TTM Sep 
(CAD)             Q3 2026       2025      YTD 2026      2025      30, 2026      30, 2025 
---------------  ----------  ----------  ----------  ----------  ----------  ----------- 
Pharmaceutical 
 Sales           11,530,182    +5%       33,443,654    +6%       42,837,694   +7% 
Oral Health 
 Sales            7,814,229         n/a  19,023,604         n/a  19,023,604          n/a 
Insecticide 
 Sales              740,176   -39%        1,398,274   -26%        1,676,157  -15% 
---------------  ----------  ----   ---  ----------  ----   ---  ----------  --- ----- 
Total Company 
 Sales           20,084,587   +64%       53,865,532   +61%       63,537,455  +51% 
---------------  ----------  ----   ---  ----------  ----   ---  ----------  --- ----- 
EBITDA(1)         5,572,805   +53%       14,188,144   +48%       16,716,705  +41% 
---------------  ----------  ----   ---  ----------  ----   ---  ----------  --- ----- 
Net Income 
 After Taxes 
 (NIAT)           2,860,465    +7%        8,054,721   +15%       10,046,509  +16% 
---------------  ----------  ----   ---  ----------  ----   ---  ----------  --- ----- 
Fully Diluted 
 EPS                   0.25    +8%             0.70   +15%             0.87  +16% 
---------------  ----------  ----   ---  ----------  ----   ---  ----------  --- ----- 
 
   -- Q3 2026 was second full quarter of financial results contributed by Oral 
      Health segment following March 1, 2026 acquisition of Oral Science Inc.: 
 
          -- $7.8 million sales 
 
          -- $1.6 million EBITDA1 
 
          -- $1.2 million NIAT (before $0.83 million amortization expense on 
             acquired intangible assets) 
 
   -- Q3 2026 consolidated EBITDA1 margin:   28% to sales 
 
   -- YTD 2026 consolidated EBITDA1 margin: 26% to sales (27% to sales - 
      adjusted for one-time acquisition costs) 
 
   -- Return on Average Equity for the trailing twelve months ('TTM') ended 
      September 30, 2026 was 23%, increasing from 22% for TTM September 30, 
      2025 
 
   -- During YTD 2026, repurchased and cancelled a total of 326,500 common 
      shares under a Normal Course Issuer Bid (NCIB) 
 
   -- Paid quarterly cash dividends of $0.055 per common share on March 13, 
      2026, June 15, 2026, and September 15, 2026 
 
   -- Subsequent to quarter-end: 
 
          -- Repaid remaining $2 million balance of acquisition debt on October 
             1, 2026 
 
          -- Declared subsequent cash dividend of $0.055 per common share to be 
             paid on December 15, 2026 

"Our recently acquired Oral Health business continued to perform well in Q3 2026, its second full quarter of operations as part of BioSyent," commented Mr. René Goehrum, President and CEO of BioSyent. "When combined with our existing pharmaceutical brands, the Oral Science product catalogue gives us a broad platform for continued future growth, both in Canada and internationally. With combined operating cash flows of $6.0 million in Q3 2026, we were able to deploy $1.7 million in share buybacks under our ongoing Normal Course Issuer Bid and $0.6 million in dividends during the quarter while continuing to invest in our brands, including Thyconvi(R) , as we prepare to launch this product in Canada in the first quarter of 2027. Additionally, we have fully repaid our remaining acquisition debt of $2.0 million, leaving us with a clean balance sheet and strong cash position to take advantage of future opportunities and to hedge against future risks. I look forward to reporting on our continuing progress in 2027."

The CEO's presentation on the Q3 2026 Results is available at the following link: www.biosyent.com/investors/

The Company's Interim Unaudited Condensed Consolidated Financial Statements and Management's Discussion and Analysis for the three and nine months ended September 30, 2026 and 2025 will be posted on www.sedarplus.ca on November 17, 2026.

The Company further announces that its Board of Directors has approved a grant of 2,765 Restricted Share Units ("RSUs") to certain directors of the Company pursuant to the Company's RSU Plan. These RSUs will fully vest within three years on the third anniversary of the applicable grant date.

For a direct market quote for the TSX Venture Exchange and other Company financial information, please visit www.tmxmoney.com.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty healthcare products company focused on acquiring or in-licensing, marketing and distributing innovative pharmaceutical and oral health products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its Pharmaceutical and Oral Health businesses, both in Canada and internationally.

As of the date of this press release, the Company has 11,235,488 common shares outstanding.

 
                                                BioSyent Inc. 
                             Interim Unaudited Condensed Consolidated Statements 
                                            of Comprehensive Income 
 
In Canadian Dollars      Q3 2026         Q3 2025       % Change       YTD 2026         YTD 2025       % Change 
--------------------                                              ----------------  --------------  ---------- 
Net Revenues          20,084,587      12,221,804         +64%       53,865,532      33,380,060        +61% 
Cost of Goods Sold     6,115,631       2,954,884        +107%       15,758,523       7,863,386       +100% 
Gross Profit          13,968,956       9,266,920         +51%       38,107,009      25,516,674        +49% 
Operating Expenses 
 and Finance 
 Income/Costs          9,561,862       5,617,478         +70%       26,444,506      15,965,050        +66% 
Net Income Before 
 Tax                       4,407,094   3,649,442         +21%       11,662,503(++)   9,551,624        +22% 
Tax (including 
 Deferred Tax)         1,546,629         967,102         +60%        3,607,782       2,531,180        +43% 
Net Income After Tax       2,860,465   2,682,340          +7%        8,054,721(++)   7,020,444        +15% 
Net Income After Tax 
 % to Net Revenues            14%             22%                           15%             21% 
EBITDA(1)              5,572,805       3,632,399         +53%       14,188,144       9,594,195        +48% 
EBITDA(1) % to Net 
 Revenues                     28%             30%                           26%             29% 
--------------------  ----------      ----------      ----------  ------------      ----------      ---------- 
 

Net of $825,000 amortization expense on intangible assets recognized in acquisition of Oral Science Inc.

++ Net of $1,925,000 amortization expense on intangible assets recognized in acquisition of Oral Science Inc.

 
                                BioSyent Inc. 
             Interim Unaudited Condensed Consolidated Statements 
                             of Financial Position 
 
 
                  AS AT   September 30, 2026    December 31, 2025    % Change 
                         --------------------  -------------------  ---------- 
ASSETS 
 
Cash, cash equivalents 
 and short-term 
 investments              $        16,016,878   $       28,651,823     -44% 
Trade and other 
 receivables                        7,600,027            4,456,562      71% 
Inventory                           9,797,612            6,416,204      53% 
Prepaid expenses and 
 deposits                           1,912,732              187,977     918% 
Derivative asset                       17,174                    -       - 
Loans receivable - 
 current                               72,660               80,395     -10% 
                                                   --------------- 
CURRENT ASSETS                     35,417,083           39,792,961     -11% 
                             ----------------      ---------------  ------ 
 
Long term investments                       -            3,293,957    -100% 
Loans receivable -- 
 non-current                                -               61,799    -100% 
Deferred tax asset                    473,452              510,932      -7% 
Property and equipment              1,439,965              982,737      47% 
Intangible assets                  21,695,949            4,797,073     352% 
Goodwill                            5,928,817                    -       - 
                             ----------------      ---------------  ------ 
TOTAL NON CURRENT 
 ASSETS                            29,538,183            9,646,498     206% 
TOTAL ASSETS              $        64,955,266   $       49,439,459      31% 
                             ================      ===============  ====== 
 
LIABILITIES AND 
SHAREHOLDERS' EQUITY 
 
CURRENT LIABILITIES       $         9,806,753   $        7,215,608      36% 
SHORT TERM DEBT                     2,000,000                    -       - 
CONTINGENT 
 CONSIDERATION                      5,977,915                    -       - 
NON CURRENT LIABILITIES               626,062              758,345     -17% 
TOTAL SHAREHOLDERS' 
 EQUITY                            46,544,536           41,465,506      12% 
TOTAL LIABILITIES AND 
 SHAREHOLDERS' EQUITY     $        64,955,266   $       49,439,459      31% 
                             ================      ===============  ====== 
 
   1. EBITDA is a Non-IFRS Financial Measure. The term EBITDA does not have any 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment